JPRN-jRCT2080220152UnknownPhase 2
Efficacy and Safety of AAE581 in postmenopausal women with Osteopenia/Osteoporosis.
ovartis Pharma K.K.0 sites160 target enrollmentStarted: October 20, 2005Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Sponsor
- Enrollment
- 160
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 50age old to <= 75age old (—)
- Sex
- Female
Inclusion Criteria
- •Inclusion criteria
- •- Low spine Bone Mineral Density
- •- 0 to 1 prevalent fracture in non lumber spine
- •Exclusion criteria
- •- History or presence of any bone disease other than osteopenia/osteoporosis
- •- Previous treatment with other anti-osteoporosis agent( Wash out required)
- •- Evidence of vitamin D deficiency
- •Other protocol-defined exclusion criteria may apply.
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Completed
Phase 2
Safety and Efficacy of AAE581 in Postmenopausal Women With OsteoporosisOsteoporosisNCT00100607Novartis Pharmaceuticals676
Completed
Phase 2
Efficacy and Safety of AAE581 in Postmenopausal Women With Osteopenia/Osteoporosis.OsteoporosisNCT00170911Novartis Pharmaceuticals160
Recruiting
Not Applicable
Efficacy and safety of NET-1601 on menopausal symptoms; A 12week, multi-center, randomized, double-blind, placebo-controlled clinical trialKCT0004716aturalendo Tech100
Recruiting
Not Applicable
Effects of Testosterone and Oestradiol Therapy on Clinical Indices and Biomarkers of Dry Eye in Post Menopausal WomeEye - Diseases / disorders of the eyeDry EyeACTRN12612000281897School of Optometry and Vision Science80
Unknown
Not Applicable
Effectiveness and Safety of Fulvestrant in Postmenopausal Women With Advanced Breast Cancer HR+, HER2-Breast Neoplasm FemaleNCT05140655Dr. Reddy's Laboratories SAS40